Drugs that contain Naloxone Hydrochloride; Oxycodone Hydrochloride

1. List of Targiniq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(2 years from now)

US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8969369 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9161937 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9345701 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9084729 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9283216 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9056051 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9283221 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9168252 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9511066 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US8846090 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(a month from now)

US9555000 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(a month from now)

US9907793 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(a month from now)

US8846091 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(a month from now)

Market Authorisation Date: 23 July, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate by providing an abuse-deterrent oral controlled release combination drug product

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic